The origin of Montisera’s compound is deep in Finnish nature as it is extracted from spruce (Picea abies), the Green, renewable Gold of Finland. ”It is exceptional to have a patent issued for an extract like this. We are proud, of course, of the work done in Finland, in all of the companies involved, and the FuBio program of Finnish Bioeconomy Cluster FIBIC Ltd (now CLIC Innovation Ltd) where the work was originally initiated. To our knowledge there are only a small number of patents globally issued within this area, and now we have one of those.”, says Heikki Vuorikoski, Business Development director of Montisera and one of the inventors of the product.
Lower urinary tract (LUT) diseases cover all diseases that cause lower urinary tract symptoms, including various functional disorders and diseases of the bladder, the prostate and the urethra. The most common diseases associated with LUT symptoms related to the prostate in men are prostatitis, an umbrella term referring to several types of prostatitis, such as chronic prostatitis/chronic pelvic pain syndrome, and benign prostatic hyperplasia (BPH). In women, common diseases related to the bladder are interstitial cystitis/painful bladder syndrome (IC/PBS) and urinary incontinence.
Mira Povelainen, CEO of Montisera: “The LUTS are associated with high personal and societal costs, both in direct medical costs as well as indirect losses in daily functioning - the burden on health services is substantial“. Despite the prevalence and incidence of these diseases and symptoms, there is still a lack of effective treatment. Montisera is seeking partners in order to take this potential finding further for the patients’ relief and treatment. “We are operating in close collaboration with University of Turku, Department of Cell Biology and Anatomy, Turku, Finland. The research group of Adjunct Professor Johanna Tuomela has been working with this product from its beginning. Tuomela’s group and the key inventor M.Sc Yvonne Konkol continue studies regarding the mode of the action of the spruce extract. Results will be a base of new clinical applications and the outline of Konkol’s doctoral thesis.”, says Povelainen.
For more information please contact:
Business Development Director Heikki Vuorikoski, tel. +358 40 7562 427
About Montisera Ltd
Founded in 2012, Montisera is a privately owned, Finnish biopharmaceutical company focused on discovering, developing and commercializing novel bioactive compounds from its own and its partners’ product platforms on a broad range of disease areas. Montisera utilises a novel drug development strategy, emphasising the power of cooperation between drug development companies, biotechnology companies, the academic world, individual scientists and investors. In August 2014 Montisera was granted US and EPO patents for the use of Montisera_D15, a novel 6,7-disubstituted-isoquinoline derivatives as a medicament, particularly in the treatment of alcoholism, drug addiction and CNS related diseases. In 2015 the Finnish Medicines Agency listed Montisera_D15 as a medicinal product.
This news release may contain forward-looking statements that reflect Montisera’s current expectations regarding future events, including statements about whether the subject patent would be issued and adequately protect Montisera against competition, Montisera’s plan to protect the commercial potential of its product candidates, and the future status of pending patent applications. Forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein, and depend on a number of factors, including (inter alia) the success of Montisera’s research strategies, the applicability of the discoveries made therein, the successful and timely completion of uncertainties related to the regulatory process, and the acceptance of products by consumer and medical professionals. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which are effective only as of the date hereof. Montisera undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.